Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-08 3:42 pm Purchase | 2023-02-08 | 13G | C4 Therapeutics, Inc. CCCC | Wasatch Advisors LP | 5,775,698 11.800% | 789,626 (+15.84%) | Filing History |
| 2023-01-31 1:58 pm Purchase | 2022-12-31 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 3,621,133 7.400% | 215,151 (+6.32%) | Filing History |
| 2022-06-10 08:44 am Purchase | 2022-05-31 | 13G | C4 Therapeutics, Inc. CCCC | ArrowMark Colorado Holdings, LLC | 5,413,728 11.090% | 5,413,728 (New Position) | Filing History |
| 2022-06-06 1:31 pm Purchase | 2022-06-06 | 13G | C4 Therapeutics, Inc. CCCC | Wasatch Advisors LP | 4,986,072 10.200% | 4,986,072 (New Position) | Filing History |
| 2022-02-14 5:20 pm Sale | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Perceptive Advisors LLC | 2,208,913 4.500% | -949,653 (-30.07%) | Filing History |
| 2022-02-14 3:11 pm Sale | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Cormorant Asset Management, LP | 0 0.000% | -2,490,065 (Position Closed) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | T. Rowe Price Associates, Inc. | 4,084,798 8.400% | 4,084,798 (New Position) | Filing History |
| 2022-02-14 09:31 am Purchase | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | RTW Investments, LP | 2,494,965 5.100% | 2,494,965 (New Position) | Filing History |
| 2022-02-04 4:12 pm Purchase | 2021-12-31 | 13G | C4 Therapeutics, Inc. CCCC | BlackRock Inc. BLK | 3,405,982 7.000% | 3,405,982 (New Position) | Filing History |
| 2021-06-15 08:31 am Sale | 2021-06-14 | 13D | C4 Therapeutics, Inc. CCCC | COBRO VENTURES OPPORTUNITY FUND L.P. | 2,127,999 4.900% | -2,213,931 (-50.99%) | Filing History |
| 2021-02-16 3:48 pm Purchase | 2020-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Perceptive Advisors LLC | 3,158,566 7.300% | 3,158,566 (New Position) | Filing History |
| 2021-02-16 3:03 pm Sale | 2020-12-31 | 13G | C4 Therapeutics, Inc. CCCC | Cormorant Asset Management, LP | 2,490,065 5.790% | -3 (-0.00%) | Filing History |